Common FDA Inspection Findings in Radiopharmaceutical Facilities — and How to Prevent Them

Example of a modern radiopharmaceutical hot cell used in GMP manufacturing. Proper qualification, monitoring, and integration with radiation safety controls are critical areas of focus during FDA inspections under 21 CFR Part 212.

Radiopharmaceutical manufacturing operates under unique pressures. Short half-lives, specialized containment, and the dual requirements of cGMP and radiation safety create conditions that differ significantly from traditional pharmaceutical operations. FDA inspections of these facilities, primarily conducted under 21 CFR Part 212, frequently uncover recurring gaps.

After nearly 30 years in GxP and extensive work with radiopharmaceutical operations, I consistently see the same patterns. Below are some of the most common findings and practical ways to address them.

1. Incomplete Hot Cell and Isolator Qualification

Many sites have initial IQ/OQ documentation but lack robust performance qualification or ongoing monitoring records. Inspectors expect clear acceptance criteria, evidence of continued state of control, and proper change control when modifications occur.

Prevention tip: Maintain a living qualification status for all critical containment equipment and trend performance data regularly.

2. Weak Integration of Radiation Safety (ALARA) with cGMP

Radiation safety and quality systems are often managed as separate programs. FDA expects practical integration — procedures, training, and documentation should show that ALARA principles are embedded in manufacturing operations.

3. Documentation Gaps Under Time Pressure

Short half-life products require rapid execution. This frequently leads to incomplete contemporaneous records, missing second-person verifications, or delayed entries. Data integrity expectations still fully apply.

4. Environmental Monitoring and Trending Weaknesses

Facilities may collect data but fail to trend it effectively or respond to excursions in a timely, risk-based manner.

5. Supplier Oversight for Critical Materials

Isotopes, precursors, and sterile components require strong qualification and ongoing monitoring. Gaps here commonly appear during inspections.

Strengthening Inspection Readiness

Sites that perform well typically maintain:

• Clear ownership of processes

• Strong collaboration between Quality, Production, and Radiation Safety

• Regular internal audits focused on 21 CFR 212 expectations

• Effective CAPA that prevents recurrence

  
  

I help radiopharmaceutical manufacturers and PET centers identify and close these gaps through targeted audits, mock inspections, and practical remediation support.

Learn more about our radiopharmaceutical services: https://www.gxpauditconsult.com/services/radiopharma

Contact us: https://www.gxpauditconsult.com/contact-us